Market Eyes LiveAxsome Therapeutics, Inc (AXSM) Stock Rating & Analysis
MELANY's data-driven read on Axsome Therapeutics, Inc.
Why AXSM scores 73/100
MELANY scores Axsome Therapeutics, Inc 73/100 by weighing eight factors. Here is how AXSM breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
- Gross margin 93%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Earnings in 0 days (strong beat history)
What Wall Street price targets and revisions are signalling.
- Analyst targets 28% upside
Near-term events that could move the stock.
- Earnings in 0 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for AXSM
- Earnings report in 0 days, binary outcome can move 10%+ either way
- High debt-to-equity ratio 4.0x, rate-sensitive balance sheet
- Operating margin -33%, currently unprofitable on a trailing basis
- Negative free cash flow, company consuming cash, not generating it
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Axsome Therapeutics, Inc sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 66/100 for strength. Theme strength feeds AXSM's momentum and catalyst factors above.
AXSM trade plan (members only)
MELANY has a full position plan for Axsome Therapeutics, Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates AXSM
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Axsome Therapeutics, Inc's 73/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about AXSM
Is Axsome Therapeutics, Inc (AXSM) a buy?
As of 2026-08-10, MELANY rated Axsome Therapeutics, Inc Highest Conviction with a composite score of 73/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Axsome Therapeutics, Inc's MELANY score?
Axsome Therapeutics, Inc (AXSM) has a MELANY composite score of 73/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the AXSM stock rating calculated?
MELANY scores AXSM from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Axsome Therapeutics, Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Axsome Therapeutics, Inc (AXSM) Highest Conviction with a composite of 73/100 as of 2026-08-10. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the AXSM stock price forecast?
MELANY does not publish price targets or forecasts for AXSM. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 73/100 across eight factors for Axsome Therapeutics, Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is AXSM stock overvalued or undervalued?
MELANY's valuation factor currently reads 36/100 for Axsome Therapeutics, Inc, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives AXSM's read.
What price should I buy AXSM at?
Rather than chasing the current price, MELANY computes a smart entry zone for AXSM: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying AXSM stock?
The top risks MELANY currently flags for Axsome Therapeutics, Inc: Earnings report in 0 days, binary outcome can move 10%+ either way; High debt-to-equity ratio 4.0x, rate-sensitive balance sheet; Operating margin -33%, currently unprofitable on a trailing basis; Negative free cash flow, company consuming cash, not generating it; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Axsome Therapeutics, Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 25/100 for Axsome Therapeutics, Inc, and earnings track record, at 59/100. The 73/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will AXSM stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 64/100 for AXSM right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this AXSM rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-10. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores AXSM continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
AXSM's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.